Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GILD

Gilead Sciences, Inc.

Dec 08 • 04:00PM ET

79.02

Dollar change +0.97
Percentage change 1.24	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX, S&P 500	P/E	16.94	EPS (ttm)	4.66	Insider Own	0.08%	Shs Outstand	1.25B	Perf Week	1.76%
Market Cap	98.46B	Forward P/E	10.83	EPS next Y	7.30	Insider Trans	-1.29%	Shs Float	1.25B	Perf Month	1.44%
Income	5.88B	PEG	4.11	EPS next Q	1.79	Inst Own	85.32%	Short Float / Ratio	1.46% / 3.12	Perf Quarter	2.57%
Sales	27.26B	P/S	3.61	EPS this Y	-6.56%	Inst Trans	0.86%	Short Interest	18.13M	Perf Half Y	1.15%
Book/sh	17.89	P/B	4.42	EPS next Y	7.59%	ROA	9.41%	Target Price	89.82	Perf Year	-9.99%
Cash/sh	6.40	P/C	12.35	EPS next 5Y	4.12%	ROE	27.08%	52W Range	72.87 - 89.74	Perf YTD	-7.96%
Dividend	3.08	P/FCF	12.54	EPS past 5Y	0.73%	ROI	12.91%	52W High	-11.95%	Beta	0.25
Dividend %	3.90%	Quick Ratio	1.20	Sales past 5Y	1.18%	Gross Margin	80.28%	52W Low	8.45%	ATR	1.41
Employees	17000	Current Ratio	1.34	Sales Q/Q	0.59%	Oper. Margin	34.94%	RSI (14)	58.60	Volatility	1.84% 1.74%
Optionable	Yes	Debt/Eq	1.12	EPS Q/Q	22.25%	Profit Margin	21.55%	Rel Volume	1.11	Prev Close	78.05
Shortable	Yes	LT Debt/Eq	1.04	Earnings	Nov 07 AMC	Payout	80.25%	Avg Volume	5.81M	Price	79.02
Recom	2.12	SMA20	3.90%	SMA50	2.65%	SMA200	0.97%	Volume	6,474,831	Change	1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight	$60 → $76
Oct-28-22	Upgrade	Truist	Hold → Buy	$76 → $91
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight	$79 → $96
Oct-28-22	Reiterated	Wells Fargo	Equal Weight	$74 → $75
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform	$79 → $82
Oct-28-22	Reiterated	JP Morgan	Overweight	$80 → $87
Oct-28-22	Reiterated	Jefferies	Buy	$78 → $86
Oct-28-22	Reiterated	Cowen	Outperform	$75 → $80
Oct-28-22	Reiterated	BMO Capital Markets	Market Perform	$63 → $72
Oct-04-22	Upgrade	JP Morgan	Neutral → Overweight	$72 → $80
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$70

Show Previous Ratings

Dec-07-23 11:30AM	Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report? (Zacks)
10:40AM	Gilead Sciences: The Bull Case Is More Powerful Than You Think (GuruFocus.com)
Dec-06-23 09:05PM	Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023 (ACCESSWIRE)
Dec-04-23 03:06PM	5 Best High Yield Stocks To Buy (Insider Monkey)
Dec-01-23 03:15PM	Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt (ACCESSWIRE)
08:30AM	Loading…
Nov-30-23 08:30AM	Gileads Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023 (Business Wire)
08:30AM	2 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Nov-29-23 07:05AM	Gilead to lay off staff at cell therapy unit Kite (BioPharma Dive)
Nov-28-23 01:34PM	AWS expands big pharma partnerships on manufacturing, AI, and R&D (Yahoo Finance)
01:34PM	AWS expands big pharma partnerships in manufacturing, AI, and R&D (Yahoo Finance)
08:15AM	Gilead's Ambition: To Help End the HIV Epidemic (ACCESSWIRE)
Nov-26-23 06:55AM	3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later (Motley Fool)
06:51AM	15 Best Drug Stocks To Invest In (Insider Monkey)
Nov-21-23 08:25AM	Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas (ACCESSWIRE)
Nov-20-23 06:52AM	20 Most Valuable Healthcare Companies in the World (Insider Monkey)
09:47AM	Loading…
Nov-15-23 09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
06:00AM	Kite and Arcellx Announce Expansion in Strategic Partnership (Business Wire)
06:00AM	ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP (PR Newswire)
Nov-14-23 08:45AM	Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS (ACCESSWIRE)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
Nov-09-23 09:00AM	Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research (ACCESSWIRE)
08:45AM	Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance (PR Newswire)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 07:13PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
04:01PM	Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat (Investor's Business Daily)
03:50PM	Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:58AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
09:52AM	Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales (Zacks)
09:14AM	Midday movers: Warner Bros Discovery, Eli Lilly, Robinhood and more (Investing.com)
07:40AM	Q3 2023 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Loading…
02:11AM	Gilead reports better-than-expected earnings amid strong cancer drug sales (Investing.com)
12:06AM	The Gilead Sciences Inc (GILD) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-07-23 09:15PM	Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript (Motley Fool)
06:00PM	Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:50PM	UPDATE 1-Gilead quarterly results beat Street estimates as lower taxes boost profit (Reuters)
04:19PM	Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs (Investor's Business Daily)
04:12PM	Gilead: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Gilead quarterly results beat Street estimates as lower taxes boost profit (Reuters)
04:02PM	Gilead Sciences Announces Third Quarter 2023 Financial Results (Business Wire)
04:01PM	Gilead quarterly results beat Street estimates as profit up on lower taxes (Reuters)
09:30AM	Gilead Sciences: Advancing Global Health Equity in Tropical Regions (ACCESSWIRE)
Nov-06-23 05:00PM	Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers (Business Wire)
Nov-03-23 11:00AM	Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting 2023 (Business Wire)
Nov-02-23 10:00AM	Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline (Zacks)
09:15AM	Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 (Business Wire)
Oct-31-23 10:01AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
08:20AM	Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic (ACCESSWIRE)
07:30AM	Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer (Business Wire)
Oct-30-23 05:50PM	Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know (Zacks)
11:59AM	Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store? (Zacks)
05:46AM	11 Best Pharma Stocks To Buy Now (Insider Monkey)
Oct-26-23 07:30AM	3 Pharma Stocks That Are Screaming Buys in October (Motley Fool)
Oct-25-23 04:49AM	USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Oct-24-23 05:50PM	Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider (Zacks)
12:00PM	Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS (Business Wire)
09:15AM	3 Biotech Stocks With Decent Dividend for a Steady Return (Zacks)
Oct-23-23 06:00PM	Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Oct-20-23 05:10AM	New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca for Adults With Multi-Drug Resistant HIV (Business Wire)
Oct-19-23 11:40AM	GILD or VRTX: Which Is the Better Value Stock Right Now? (Zacks)
09:01AM	Insider Sell: CFO Andrew Dickinson Sells 5,000 Shares of Gilead Sciences Inc (GuruFocus.com)
03:00AM	Real-World Evidence Reinforces Biktarvy as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities (Business Wire)
Oct-18-23 04:09PM	Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock (Investor's Business Daily)
03:00AM	Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program (Business Wire)
Oct-17-23 09:30AM	Gilead Sciences: Leading With Passion and Purpose: Sandras Story (ACCESSWIRE)
07:00AM	Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases (Business Wire)
Oct-16-23 06:00PM	Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
03:14PM	Jim Simons Stock Portfolio: Top 10 Stock Picks (Insider Monkey)
07:30AM	Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023 (Business Wire)
01:01AM	Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023 (Business Wire)
Oct-15-23 10:00AM	2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now (Motley Fool)
Oct-12-23 04:05PM	Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 (Business Wire)
09:00AM	Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032 (GlobeNewswire)
Oct-11-23 06:35AM	AQR Capital Management: AUM, Performance, Stock Picks (Insider Monkey)
03:54AM	Should You Invest in Gilead Sciences (GILD)? (Insider Monkey)
Oct-09-23 06:00PM	Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
Oct-03-23 08:30AM	Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023 (Business Wire)
Oct-02-23 07:09PM	Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs (InvestorPlace)
06:00PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know (Zacks)
09:00AM	Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders (Business Wire)
Sep-30-23 06:55AM	3 Magnificent Dividend Stocks to Buy in October (Motley Fool)
Sep-29-23 03:24PM	20 Countries with Lowest Teenage Pregnancy Rates in the World (Insider Monkey)
Sep-26-23 06:00PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
11:35AM	Unveiling Gilead Sciences (GILD)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-21-23 01:54PM	3 Bargain Stocks to Buy in a Market That's Priced for Perfection (Motley Fool)
08:00AM	Blockbuster Cancer Treatment Stymied by Supply Chainfor Now (The Wall Street Journal)
Sep-20-23 07:51AM	Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients (Zacks)
Sep-19-23 08:30AM	CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment (Business Wire)
Sep-18-23 03:49PM	With ex-Vertex leader out as CEO, biotech makes layoffs, leaves Watertown HQ (American City Business Journals)
04:00AM	Kites Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma (Business Wire)
Sep-14-23 07:03AM	Unraveling Gilead Sciences Inc's Dividend Performance and Sustainability (GuruFocus.com)
Sep-13-23 07:58AM	Investor Concerns Dragged Gilead Sciences (GILD) in Q2 (Insider Monkey)
Sep-12-23 05:50PM	Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know (Zacks)
02:00PM	Time for Gilead Sciences-Heavy ETFs? (Zacks)
Sep-11-23 11:20AM	Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study (Zacks)
Sep-10-23 03:01AM	Gileads Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer (Business Wire)
Sep-08-23 04:50PM	The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month (Investor's Business Daily)
04:46PM	US STOCKS-S&P 500 closes up slightly ahead of US inflation data (Reuters)
02:26PM	US STOCKS-Wall St rises as megacaps gain, yields slip ahead of US inflation data (Reuters)
12:06PM	US STOCKS-Wall St rises as megacaps gain, yields slip ahead of key inflation data (Reuters)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dickinson Andrew D	Chief Financial Officer	Oct 17	Sale	80.00	5,000	400,017	104,003	Oct 18 04:31 PM
Parsey Merdad	Chief Medical Officer	Sep 12	Sale	76.99	1,501	115,562	70,130	Sep 13 06:50 PM
Dickinson Andrew D	Chief Financial Officer	Jul 20	Sale	80.00	5,000	400,000	107,587	Jul 21 05:30 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 28	Buy	19.26	1,010,000	19,452,600	14,823,029	Jun 30 03:12 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 27	Buy	3.75	2,930,870	10,990,762	16,635,286	Jun 28 05:17 PM
Parsey Merdad	Chief Medical Officer	Jun 13	Sale	76.90	1,485	114,197	29,402	Jun 14 05:48 PM
Parsey Merdad	Chief Medical Officer	Mar 13	Sale	78.99	6,126	483,893	70,130	Mar 14 06:20 PM
Lofton Kevin E	Director	Mar 09	Option Exercise	52.38	8,442	442,192	8,442	Mar 10 05:23 PM
Parsey Merdad	Chief Medical Officer	Mar 01	Sale	79.96	12,984	1,038,225	70,130	Mar 02 07:01 PM
Parsey Merdad	Chief Medical Officer	Dec 30	Sale	85.33	553	47,187	45,556	Jan 03 08:05 PM
Dickinson Andrew D	Chief Financial Officer	Dec 10	Option Exercise	0.00	1,027	0	69,695	Dec 13 03:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc.

Upgrade your FINVIZ experience